Prostate cancer is the most common cancer in American men, and the overwhelming majority of those diagnoses are one specific type. Prostatic adenocarcinoma is a cancer that begins in the glandular cells of the prostate — the cells that produce seminal fluid. It accounts for roughly 95 percent of all prostate cancers. When a man is told he has prostate cancer, in almost every case what he actually has is prostatic adenocarcinoma.
What Is Prostatic Adenocarcinoma?
Adenocarcinoma means cancer that starts in glandular tissue. The prostate is a gland, and most of it is made up of tiny glandular structures lined with cells that secrete fluid. When those cells accumulate genetic changes and begin growing out of control, the result is prostatic adenocarcinoma.
The prostate sits just below the bladder and in front of the rectum. It surrounds the urethra, the tube that carries urine out of the body. This location explains many of the symptoms that can appear as the gland enlarges — whether from cancer or from the benign enlargement that affects most older men.
Prostatic adenocarcinoma usually starts in the peripheral zone of the prostate, the outer region farthest from the urethra. That is why it often causes no symptoms in its early stages. By the time a tumor grows large enough to press on the urethra, it is often more advanced. This is also why digital rectal exams can sometimes detect it — the peripheral zone is the area a doctor can feel.
Other, rarer types of prostate cancer exist. These include ductal adenocarcinoma, small cell carcinoma, and squamous cell carcinoma. They behave differently and are treated differently. But they make up a small minority of cases.
What Causes Prostatic Adenocarcinoma?
Cancer develops when cells acquire mutations in genes that control growth and division. In prostatic adenocarcinoma, those mutations accumulate over years or decades. The exact triggers are not fully understood, but researchers have identified several factors that raise or lower risk.
The strongest known risk factors are age, family history, and ancestry. Risk rises sharply after age 50. Having a father or brother with prostate cancer roughly doubles a man’s risk. Men of African ancestry have both a higher incidence and a higher risk of aggressive disease compared with men of European ancestry. The reasons are not fully explained, but they likely involve a mix of genetic and social factors, including differences in access to care.
Genetics play a meaningful role. Inherited mutations in genes such as BRCA1, BRCA2, and HOXB13 are linked to higher prostate cancer risk. These same genes are associated with breast and ovarian cancer in women. Men with strong family histories of those cancers may also face elevated prostate cancer risk.
Diet and lifestyle are harder to pin down. Some studies suggest that diets high in certain fats or low in vegetables may play a role, but results have been inconsistent. No single food or nutrient has been shown to cause or prevent prostate cancer with certainty. This is an area where the evidence is genuinely mixed.
What Are the Symptoms of Prostatic Adenocarcinoma?
Early prostatic adenocarcinoma usually causes no symptoms at all. That is the central challenge of this disease. Most cases are found through screening, not because a man felt something was wrong.
When symptoms do appear, they often reflect obstruction of the urinary tract or local spread. They can include:
- Weak or interrupted urine flow
- Frequent urination, especially at night
- Difficulty starting or stopping urination
- Blood in urine or semen
- Pain or burning during urination
- Painful ejaculation
- Persistent pain in the hips, lower back, or pelvis
Here is an important point that is often misunderstood. These symptoms are far more commonly caused by benign prostatic hyperplasia (BPH) or prostatitis than by cancer. BPH is a non-cancerous enlargement of the prostate that affects most men as they age. Having urinary symptoms does not mean you have cancer. But it does mean you should get evaluated.
Advanced disease can spread to lymph nodes and bones. Bone pain, unexplained weight loss, or fatigue may appear when cancer has spread beyond the prostate.
How Is Prostatic Adenocarcinoma Diagnosed?
Diagnosis usually begins with a prostate-specific antigen (PSA) blood test, a digital rectal exam, or both. PSA is a protein produced by prostate cells. Higher levels can indicate cancer, but they can also rise from BPH, infection, or recent procedures. PSA is not a cancer-specific test.
If PSA is elevated or a rectal exam finds something abnormal, the next step is usually a prostate biopsy. A doctor removes small samples of tissue using a thin needle, often guided by ultrasound or MRI. A pathologist then examines the tissue under a microscope.
The pathologist assigns a Gleason score, which grades how abnormal the cancer cells look compared with normal prostate cells. The score ranges from 6 to 10. A newer system called Grade Group condenses this into groups 1 through 5. Higher grades mean the cancer is more likely to grow and spread quickly.
Imaging tests such as MRI, CT scans, or bone scans may be used to see whether cancer has spread. Not every man needs every test. The choice depends on PSA level, Gleason score, and other findings.
How Is Prostatic Adenocarcinoma Treated?
Treatment depends on how aggressive the cancer is, how far it has spread, the man’s age, and his other health conditions. There is no single right answer.
For slow-growing, low-grade cancers confined to the prostate, active surveillance is often recommended. This means regular PSA tests, exams, and sometimes repeat biopsies, with treatment deferred unless the cancer shows signs of progressing. Many men with low-risk prostate cancer will never need treatment. This approach avoids the side effects of surgery or radiation for cancers that may never cause harm.
For cancers that need treatment, common options include:
- Surgery — radical prostatectomy removes the prostate gland. It can be done with open, laparoscopic, or robotic techniques.
- Radiation therapy — external beam radiation or brachytherapy (radioactive seeds placed in the prostate) destroys cancer cells.
- Hormone therapy — lowers testosterone or blocks its effects, since prostate cancer cells often depend on testosterone to grow. It is often used with radiation for higher-risk disease or for advanced cancer.
- Chemotherapy — used mainly for advanced or castration-resistant disease.
- Immunotherapy and targeted therapy — newer options for specific situations, including some advanced cancers with certain genetic features.
Each treatment carries risks. Surgery and radiation can cause urinary incontinence and erectile dysfunction. Hormone therapy can cause fatigue, hot flashes, loss of muscle mass, and bone thinning. These are real trade-offs that men and their doctors need to weigh carefully.
Treatment for prostatic adenocarcinoma has improved over the past two decades, particularly for advanced disease. But outcomes vary widely depending on stage, grade, and individual factors. No treatment is guaranteed.
What Is the Outlook for Men With Prostatic Adenocarcinoma?
Most men diagnosed with prostatic adenocarcinoma do not die from it. When the cancer is found while still confined to the prostate, the five-year relative survival rate is close to 100 percent. That figure comes from national cancer registry data and reflects a very favorable outlook for localized disease.
Outcomes are less favorable when cancer has spread to distant parts of the body. Even then, many men live for years with treatment. Prostate cancer often grows slowly, and newer therapies have extended survival for advanced disease.
It is worth understanding that survival statistics describe groups, not individuals. A man’s own outlook depends on his cancer’s grade, stage, genetic features, age, overall health, and how it responds to treatment. A doctor who knows these details can give a more meaningful picture than any general statistic.
Can Prostatic Adenocarcinoma Be Prevented?
There is no proven way to prevent prostatic adenocarcinoma. No diet, supplement, or lifestyle change has been shown in large trials to reliably prevent it.
Some research has suggested that certain habits may be associated with lower risk, including maintaining a healthy weight, staying physically active, and eating a diet rich in vegetables. But association is not the same as prevention. Trials of specific nutrients, such as vitamin E and selenium, did not show a protective effect — and one large trial found that vitamin E supplementation was actually associated with a higher risk of prostate cancer.
What men can do is make informed decisions about screening. Screening with PSA can find cancer early, when it is most treatable. But it can also find slow-growing cancers that would never have caused problems, leading to treatments with side effects. Major medical organizations differ in their screening recommendations, and the decision is best made through a conversation between a man and his doctor, weighing his individual risk factors.
Frequently Asked Questions
What is prostatic adenocarcinoma?
It is a cancer that starts in the glandular cells of the prostate, the cells that make seminal fluid. It accounts for roughly 95 percent of all prostate cancer cases.
Is prostatic adenocarcinoma curable?
When found while still confined to the prostate, it is often curable with surgery or radiation. Advanced disease that has spread beyond the prostate is generally not curable, though treatment can control it for years.
What is the difference between prostatic adenocarcinoma and prostate cancer?
Prostatic adenocarcinoma is a type of prostate cancer, not a separate disease. It is by far the most common type, while other rare forms like small cell or squamous cell carcinoma behave differently and are treated differently.
What age does prostatic adenocarcinoma usually occur?
Risk rises sharply after age 50, and most cases are diagnosed in men over 65. It is uncommon before age 40.

